Introduction
The risks of sedation in patients with respiratory failure are well known, and it appears that there is no drug with sedative, hypnotic, or tranquillizing properties which can be given with safety to these patients (Clark, Collins, and Tong, 1971) . This is unfortunate as there are many occasions when such treatment is desirable, and the statement that benzoctamine (Tacitin) when used as a tranquillizer does not cause respiratory depression (Geisler and Rost, 1970) excited our interest. We have set out to examine this claim by giving benzoctamine to patients with respiratory failure.
Patients and Methods
Altogether, 20 patients were studied on 23 admissions to hospital (12 men, mean age 63-6 years, and eight women, mean age 42-4 years). Fourteen were in respiratory failure secondary to chronic obstructive bronchitis and six had acute exacerbation of bronchial asthma. On 15 admissions the patient was given 10 mg (one tablet) of benzoctamine and on eight admissions 20 mg were given.
CHRONIC OBSTRUCTIVE BRONCHITIS
Seven patients with chronic obstructive bronchitis were studied during the first 24 hours of 10 admissions to hospital with acute on chronic respiratory failure. On six occasions the patient was given 10 mg of benzoctamine and on four occasions 20 mg were given.
On eight other occasions seven patients with chronic respiratory failure associated with chronic obstructive bronchitis were given benzoctamine during the recovery phase after an admission for acute exacerbation of symptoms. In this group 10 mg benzoctamine was prescribed on six occasions and 20 mg on the remaining two occasions.
ASTHMA
Benzoctamine tablets were given to all except one woman (Case 7) with asthma who is discussed separately. All patients with asthma were studied during the first 24 hours after admission to hospital with an acute attack of severe asthma. Two patients were given 10 mg of benzoctamine and three patients were given 20 mg.
STUDY
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured with a Vitalograph dry spirometer and peak expiratory flow rate (PEFR) was measured with a Wright peak flow meter. These measurements were made in all patients. Arterial blood samples were obtained in four patients with chronic obstructive bronchitis and three patients with asthma, and pH, oxygen, and carbon dioxide tensions were estimated using a Radiometer AMI machine. In all other studies mixed venous carbon dioxide tensions were estimated by using a rebreathing method (Campbell and Howell, 1962) .
In all patients measurements were made in the evening before the administration of benzoctamine as night sedation and were repeated the next morning. In all patients benzoctamine was given only if the clinician responsible thought sedation a desirable course of treatment. In addition to the measurements made before benzoctamine and again the next morning, the clinical state of each patient was closely observed during the night. After benzoctamine, asleep ..
Results
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Discussion Preliminary studies (Rondel, 1972) have shown that benzoctamine could be given intravenously with safety to patients with chronic respiratory failure. Five patients were studied with doses of 20-30 mg, and arterial blood gas analysis showed no change 20 minutes after injection. Other work also showed that benzoctamine did not reduce the CO, responsiveness but rather caused an increased ventilatory response to CO (Geisler and Rost, 1970) . The present study set out to extend these observations in a more realistic clinical setting. The major risk of sedatives lies in the respiratory depression that occurs in patients with acute on chronic respiratory failure (Wilson et al., 1954; Sadoul, 1965) . Our main purpose was to study the effect of benzoctamine in this situation but we have extended our observations to include patients with CO2 retention on recovery from an acute episode as well as patients with acute, severe asthma. We felt it was not justified to extend the acute parenteral studies in these groups of patients but to observe closely the effect of benzoctamine when given in a conventional manner to patients thought to require sedation. We therefore only measured Pco2 and other physiological variables before drug administration and again the next morning as this should have been sufficient to document the clinical diagnosis of CO2 narcosis, which usually appears within hours of sedation and lasts many hours even if intervention is prompt. No patient developed CO2 narcosis and no evidence for a more insidious worsening of gas exchange was found.
In summary, our initial experience with benzoctamine has been promising when used in a realistic clinical setting. In two of the patients who were very anxious and distressed by dyspnoea a dose of 40-50 mg of benzoctamine three times a day by mouth produced satisfactory clinical benefit without respiratory depression. In case 7 the benefits of sedation were clearly seen both clinically and in terms of blood gas tensions. If further experience with benzoctamine confirms its safety in these patients the place for sedation in respiratory failure should be reviewed.
No simple explanation can be given for the apparent safety of the drug in patients with respiratory failure. It is of interest that tricyclic antidepressants rarely cause respiratory depression, and we note that benzoctamine bears some resemblance to this group of drugs. Our findings may be partly explained by an earlier report in which benzoctamine had been shown to stimulate respiration in some subjects (Geisler and Rost, 1970) . These findings await confirmation by further studies of the effects of this drug on CO2 responsiveness.
Only more extensive clinical experience will show the degree of safety provided by benzoctamine when given as a hypnotic or sedative in patients with respiratory failure.
